← Browse by Condition
Medical Condition

non hodgkin lymphoma nhl

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, EARLY_Phase 1, Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — non hodgkin lymphoma nhl Clinical Trials

How many clinical trials are currently recruiting for non hodgkin lymphoma nhl?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for non hodgkin lymphoma nhl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for non hodgkin lymphoma nhl?
non hodgkin lymphoma nhl research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a non hodgkin lymphoma nhl clinical trial?
Eligibility criteria for non hodgkin lymphoma nhl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
1
Top Sponsors
Medical College of Wisconsin 1 trial
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1 trial
NOBO Medicine 1 trial

Recruiting Clinical Trials

NCT04186520 Phase 1, Phase 2
Recruiting
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Enrollment
100 pts
Location
United States
Sponsor
Medical College of Wisconsin
View Trial →
NCT07101705 EARLY_Phase 1
Recruiting
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Enrollment
40 pts
Location
China
Sponsor
Union Hospital, Tongji Medical...
View Trial →
NCT07114367 Phase 1
Recruiting
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
Enrollment
9 pts
Location
South Korea
Sponsor
NOBO Medicine
View Trial →

Related Conditions

mantle cell lymphoma mcl (1) chronic lymphocytic leukemia cll (1) follicular lymphoma (1) marginal zone lymphoma (1) diffuse large b cell lymphoma (1) primary mediastinal large b cell lymphoma pmbcl (1) central nervous system lymphoma (1) multiple myeloma mm (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology